Survival of Intravenous Chemotherapy Infusion Sites
Author Information
Author(s): J.F. Hecker
Primary Institution: Royal Postgraduate Medical School
Hypothesis
What factors are associated with the failure of intravenous infusions delivering cytotoxic drugs?
Conclusion
The study found that the survival rate of intravenous infusions delivering cytotoxic drugs was not significantly different from that of non-cytotoxic infusions.
Supporting Evidence
- Of 284 infusion sites studied, 78 (27.4%) failed.
- Cisplatin was associated with longer survival, but this was likely an artifact.
- Etoposide was the only drug associated with decreased infusion survival.
- Infusion failure was significantly more rapid in women.
Takeaway
This study looked at how long IV infusions for cancer treatment last before they fail, and found that the type of drug used doesn't make a big difference.
Methodology
Data were collected from 122 oncology patients receiving peripheral infusions, with sites inspected for signs of phlebitis and extravasation.
Potential Biases
The study may have underestimated the failure rate as some patients reported issues after discharge.
Limitations
Follow-up was only possible for a proportion of patients, and some patients reported phlebitic signs after leaving the hospital.
Participant Demographics
The study involved 122 oncology patients, with a noted effect of sex on infusion survival.
Statistical Information
P-Value
0.0014
Confidence Interval
(0.264-0.776)
Statistical Significance
p<0.05
Want to read the original?
Access the complete publication on the publisher's website